Synthetic biology is among the fastest growing fields of research with tremendous potential in industrial and health applications. Technological advances especially in DNA sequencing as well as functional genomics have provided a wealth of data that are now applied through all fields of molecular biology. Synthetic biology is heavily constrained by our ability to synthesize DNA, especially long and complex sequences such as GC-rich and repetitive motifs, however. This unmet need is exemplified by the massively increasing demand for large plasmids and expression vectors required for the development and production of complex biologics like bi-specific antibodies, fusion proteins and large payloads in gene therapy. Ribbon Biolabs has developed an entirely novel approach to lift this technological limitation by combining computational and combinatorial optimisation approaches with automation and enzymatic assembly which constitute its proprietary InfiniSynth™ platform.
Ribbon Biolabs is Synthetic Biology company whose mission is to serve the growing needs for synthetic DNA as a fundamental component for innovation in biotechnology and biopharma. By providing our customers with rapid access to DNA molecules between 10,000-30,000 bps and variant libraries thereof, we empower them to create visionary solutions and to engineer novel products in antibody development, mRNA technologies, CRISPR screenings, cell and gene therapies, and other biologics. We are based in Austria and US and seek to further expand to the APAC area in the coming years.